KR20240039030A - 5-하이드록시트립토판 위체류성 투여 형태 - Google Patents

5-하이드록시트립토판 위체류성 투여 형태 Download PDF

Info

Publication number
KR20240039030A
KR20240039030A KR1020247006922A KR20247006922A KR20240039030A KR 20240039030 A KR20240039030 A KR 20240039030A KR 1020247006922 A KR1020247006922 A KR 1020247006922A KR 20247006922 A KR20247006922 A KR 20247006922A KR 20240039030 A KR20240039030 A KR 20240039030A
Authority
KR
South Korea
Prior art keywords
htp
carbidopa
dosage form
modified release
release layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247006922A
Other languages
English (en)
Korean (ko)
Inventor
제이콥 페이드 램소우 제이콥슨
브레트 베르너
우 린
칭 시우 테이
Original Assignee
에벡시아 테라퓨틱스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에벡시아 테라퓨틱스 아이엔씨. filed Critical 에벡시아 테라퓨틱스 아이엔씨.
Publication of KR20240039030A publication Critical patent/KR20240039030A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247006922A 2021-07-30 2022-07-29 5-하이드록시트립토판 위체류성 투여 형태 Pending KR20240039030A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227915P 2021-07-30 2021-07-30
US63/227,915 2021-07-30
PCT/US2022/038914 WO2023009841A1 (en) 2021-07-30 2022-07-29 5-hydroxytryptophan gastroretentive dosage forms

Publications (1)

Publication Number Publication Date
KR20240039030A true KR20240039030A (ko) 2024-03-26

Family

ID=83049744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247006922A Pending KR20240039030A (ko) 2021-07-30 2022-07-29 5-하이드록시트립토판 위체류성 투여 형태

Country Status (14)

Country Link
US (2) US11752107B2 (https=)
EP (1) EP4362919A1 (https=)
JP (1) JP2024528125A (https=)
KR (1) KR20240039030A (https=)
CN (1) CN116801868A (https=)
AU (1) AU2022320730A1 (https=)
BR (1) BR112024001927A2 (https=)
CA (1) CA3226223A1 (https=)
CL (1) CL2024000271A1 (https=)
CO (1) CO2024002256A2 (https=)
IL (1) IL310523A (https=)
MX (1) MX2024001390A (https=)
WO (1) WO2023009841A1 (https=)
ZA (1) ZA202401725B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2024148354A1 (en) * 2023-01-06 2024-07-11 Evecxia Therapeutics, Inc. A method of enhancing 5-hydroxytryptophan (5-htp) exposure
WO2025042927A2 (en) * 2023-08-24 2025-02-27 Merck Sharp & Dohme Llc Sustained-release formulations for poorly permeable cyclic peptides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4191184A (en) 1977-01-06 1980-03-04 Carlisle Jeffrey A Intravenous infusion regulation system with reciprocal metering means
US4658038A (en) 1982-10-07 1987-04-14 Research Foundation For Mental Hygiene, Inc. N-acylated 5-hydroxytryptophan amide derivatives
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
FR2654931B1 (fr) * 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
IN186245B (https=) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US7674480B2 (en) 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060013875A1 (en) 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
BR0314804A (pt) * 2002-09-28 2005-08-02 Mcneil Ppc Inc Forma de dosagem de liberação modificada
EP1542662A1 (en) 2002-09-28 2005-06-22 McNEIL-PPC, INC. Immediate release dosage form comprising shell having openings therein
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
ITMI20041689A1 (it) 2004-09-01 2004-12-02 Bojidar Mihaylov Stankov Nuove formulazioni di rilascio controllato contenenti 5-idrossitriptofano e triptofano
US20080268045A1 (en) 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
KR20080076382A (ko) 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
EP1980743B1 (en) 2007-04-10 2015-09-09 Nissan Motor Co., Ltd. Fuel pump driving device
US8969400B2 (en) 2007-10-01 2015-03-03 Duke University Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
KR101601649B1 (ko) 2008-04-18 2016-03-09 인텍 파마 리미티드 카르비도파／레보도파 위체류 약물 전달
ZA200903854B (en) 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
JP2012500221A (ja) 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
WO2011146611A1 (en) 2010-05-18 2011-11-24 Abon Pharmaceuticals, Llc Modified gastroretentive drug delivery system for amine drugs
US20130078290A1 (en) * 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
CN103554005A (zh) 2013-11-22 2014-02-05 长沙理工大学 一种左旋5-羟基色氨酸的简便合成新方法
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
HK1258050A1 (zh) 2015-10-23 2019-11-01 Lyndra Therapeutics, Inc. 用於治疗剂缓释的胃驻留系统及其使用方法
BR112020015068A2 (pt) 2018-01-29 2021-01-05 Duke University Composições e métodos de melhoramento de biodisponibilidade de 5-hidroxitriptofano
CN112469400A (zh) * 2018-06-19 2021-03-09 新加坡国立大学 对于各种适应症的生物利用度更佳的5-羟色氨酸(5-htp)制剂
EP3820468A4 (en) * 2018-07-11 2022-03-23 Duke University Use of sustained-release 5-hydroxytryptophan in treating gastrointestinal disorders

Also Published As

Publication number Publication date
JP2024528125A (ja) 2024-07-26
BR112024001927A2 (pt) 2024-04-30
IL310523A (en) 2024-03-01
WO2023009841A1 (en) 2023-02-02
CA3226223A1 (en) 2023-02-02
US11752107B2 (en) 2023-09-12
CL2024000271A1 (es) 2024-08-16
US20230047338A1 (en) 2023-02-16
US20240108582A1 (en) 2024-04-04
EP4362919A1 (en) 2024-05-08
CO2024002256A2 (es) 2024-03-18
CN116801868A (zh) 2023-09-22
ZA202401725B (en) 2025-08-27
AU2022320730A1 (en) 2024-03-14
MX2024001390A (es) 2024-05-17

Similar Documents

Publication Publication Date Title
KR20240039030A (ko) 5-하이드록시트립토판 위체류성 투여 형태
US9301934B2 (en) Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
CN105431144A (zh) 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
JP7350715B2 (ja) 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群及び腺筋症を処置するための固形医薬製剤
JP7127832B2 (ja) マジンドールのｉｒ／ｓｒ多層錠剤及び該錠剤の注意欠陥／多動性障害（ａｄｈｄ）の治療のための使用
TW201906608A (zh) 口服固體製劑
EP2533767A1 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
AU2014350135B2 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US20110104272A1 (en) Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
WO2015051747A1 (zh) 一种普拉克索的缓释片剂与其制备方法及其用途
US20160030412A1 (en) Compositions and methods for treatment in parkinson's disease patients
US12409163B2 (en) Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
WO2024148354A1 (en) A method of enhancing 5-hydroxytryptophan (5-htp) exposure
EP4032530B1 (en) Prolonged-release furazidin composition
HK40097568A (zh) 5-羟色氨酸胃滞留剂型
TW201626990A (zh) 含有褪黑激素和舍曲林的口服複合錠劑
Gaikwad et al. Bilayer Tablet-Approach for the Treatment of Sexually Transmitted Diseases with Fixed Dose Combination
US20220184007A1 (en) Formulations
CN108066347B (zh) 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
GB2443738A (en) A sustained release methotrexate composition and methods of use thereof
EA046645B1 (ru) Фармацевтические препараты для лечения эндометриоза, миомы матки, синдрома поликистоза яичников или аденомиоза
BRPI0615577A2 (pt) composição farmacêutica de liberação prolongada, e, uso de uma composição farmacêutica de liberação prolongada
BRPI0615577B1 (pt) Composição farmacêutica de liberação prolongada e uso da mesma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201